samedan logo
 
 
 
spacer
home > ebr > summer 2019 > fighting the global threat
PUBLICATIONS
European Biopharmaceutical Review

Fighting the Global Threat

The discovery of penicillin by Alexander Fleming in 1928 revolutionised medicine. This antibiotic soon became one of the most widely used in treating common bacterial infections, as well as pneumonia, tuberculosis, syphilis, and more (1). However, the Nobel Prize winner also predicted how an irresponsible use of penicillin could lead to the development of resistant bacteria, resulting in losing the antibiotic efficacy and death caused by a lack of alternative treatments. His concern has become a real-life scenario, affecting the medical sector and animal husbandry on a global scale.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Adrian Fellows has been involved in R&D − particularly in the fields of disinfection and infection control − since 1972. He has filed numerous successful patents in these areas and others, including thermal devices and chemical specialities. Adrian filed the first patent applications for disinfectant wipes in the early 1970s, led a multinational team in an EU framework R&D program, and was a visiting research fellow at Huddersfield University, UK. Since 2005, he has been R&D director for Gama Healthcare, which has become a leading presence in global infection control. More recently, Adrian has been involved in leading collaborative projects in developing novel means to combat AMR.
spacer
Adrian Fellows
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

New study confirms that purity and type of coating biomaterials used in 2D cell culturing are crucial for efficient stem cell proliferation

Rousselot®, Darling Ingredients’ health brand and the global leader1 of collagen-based solutions, revealed the results of a new study which demonstrates that Rousselot’s ultra-pure GMP-grade2 gelatins outperformed standard non-endotoxin purified research grade gelatins and other coating materials in 2D cell culturing. Data demonstrate that endotoxin (lipopolysaccharide, LPS) levels and the nature of biomaterials used in cell coating have a significant impact on cell morphology and proliferation.
More info >>

White Papers

Six Strategies to Stretch Your Limited Drug Supply for Clinical Studies

PCI Pharma Services

Bringing a new drug to market can be a heavy financial burden on any pharmaceutical company. It has become even more burdensome over the last several years as the industry pushes the boundaries of innovation. This is because newer, often more-complex therapies not only increase risk in drug development but also drive costs even higher. A recent analysis of the investment needed to develop a new prescription medicine shows the total cost can be as high as $2.6 billion (1). That number becomes even more staggering when you consider the fact that only about 12 percent of drug candidates that make it to Phase I testing are eventually approved by the FDA (2). The investment companies lose as a result may be too devastating to their bottom line to ever recover.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement